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a b s t r a c t 
Background: Compound glycyrrhizin injection (CGI) is a preparation with glycyrrhizin as the main active 
ingredient extracted from licorice. As clinical trials suggest that CGI is effective in improving liver func- 
tion for acute icteric hepatitis in children (AIHC), this systematic review aimed to evaluate and verify its 
therapeutic effects and safety. 
Methods: Six electronic databases were searched from their inception to 15 May 2021. Randomized con- 
trolled trials (RCTs) assessing therapeutic effects and safety of CGI for AIHC were included. The risk of 
bias for each trial was assessed using the Cochrane Risk of Bias Tool 2.0. Primary outcomes were indexes 
related to liver function, including total bilirubin (TBiL), alanine aminotransferase (ALT) and aspartate 
transaminase (AST). RevMan 5.4 software was used for data analyses. The certainty of the evidence was 
assessed using the online GRADEpro tool. 
Results: Six RCTs involving 608 children were included. The overall bias was assessed as having “high 
risk of bias” in all trials. All trials compared the combination of CGI and conventional western medicine 
(CWM) with CWM alone. Regarding the effects of CGI for AIHC, results showed that CGI plus CWM was 
superior to CWM alone in reducing the levels of TBiL (mean difference (MD) = -8.19 mmol/L, 95% CI -9.86 
to -6.53), ALT (MD = -24.09 U/L, 95% CI -30.83 to -17.34) and AST (MD = -18.67 U/L, 95% CI -21.88 to 
-15.45). No trial reported adverse events. The certainty of the evidence for outcomes were all evaluated 
as low or very low. 
Conclusion: CGI may have adjuvant therapeutic effects on improving the liver function of children with 
AIHC. There is no evidence to determine the safety of CGI for AIHC. As current evidence is weak, further 
well-designed RCTs are required for verification of the therapeutic effects of CGI. 
© 2021 Korea Institute of Oriental Medicine. Published by Elsevier B.V. 
This is an open access article under the CC BY-NC-ND license 


















Acute icteric hepatitis (AIH) is one of the clinical sub-types of 
cute hepatitis caused by hepatitis A, B, C, D and/or E virus, with 
dverse changes in bilirubin as the main characteristic 1–3 . AIH de- 
elops rapidly and is highly infectious. Children are easily affected 
y hepatitis virus infection resulting in various adverse effects such ∗ Corresponding author at: Centre for Evidence-Based Chinese Medicine, Beijing 
niversity of Chinese Medicine, Beijing, China. 
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 http://creativecommons.org/licenses/by-nc-nd/4.0/ ) s imperfect organ development and a poor immune system func- 
ion. This can lead to the occurrence of hepatitis such as acute 
cteric hepatitis in children (AIHC). AIHC may lead to a variety of 
onditions (such as hepatic ascites, cirrhosis), if this cannot be re- 
olved in a timely manner it can seriously affect a child’s health 
nd life 4 . The main clinical symptoms of this disease include fever, 
epatomegaly, and pain in the liver area. Liver function exami- 
ation has shown that the levels of total bilirubin (TBiL), alanine 
minotransferase (ALT) and aspartate transaminase (AST) are sig- 
ificantly increased. an open access article under the CC BY-NC-ND license 












































































































In clinical practice, commonly used medications for the treat- 
ent of AIH include interferon, ribavirin, glutathione, etc. How- 
ver, the effectiveness of these medications is often poor. 5 Com- 
ound glycyrrhizin injection (CGI) is a colorless clear liquid pre- 
ared with glycyrrhizin as the main active ingredient, with glycine 
nd cysteine hydrochloride as additional ingredients. Glycyrrhizin 
s a compound, is an active ingredient extracted from Gan Cao 
 Glycyrrhiza uralensis Fisch. ex DC. ), has been reported to have var- 
ous important biological activities, 6 such as anti-oxidant proper- 
ies, anti-cancer properties and anti-inflammatory action. 7–9 The 
reparation is registered in China and produced by many differ- 
nt companies. In Japan, glycyrrhizin injections have been used 
s a therapeutic drug for allergy inflammation since 1948 and for 
hronic hepatitis since 1979. 10 By acting on multiple targets in in- 
ammatory pathways such as phospholipase A2 and high mobil- 
ty group protein 1, 11 , 12 glycyrrhizin can inhibit the inflammatory 
esponse, reduce the pathological damage of the liver and repair 
amaged liver cell function 13 , 14 . Additionally, glycyrrhizin belongs 
o a biological macromolecule with strong polarity, so the bioavail- 
bility of injection is higher than that of oral administration. 
Currently, many randomized controlled trials (RCTs) on CGI for 
IHC have been conducted. However, we were unable to find any 
ystematic reviews on CGI for the treatment of AIHC, which could 
rovide a high level of evidence to justify clinical practice. In order 
o further evaluate and verify the therapeutic effects and safety of 
GI for children with AIHC in improving their liver function and 
o provide better evidence for clinical practice, a systematic review 
nd meta-analysis was conducted. 
. Methods 
.1. Inclusion and exclusion criteria 
.1.1. Inclusion criteria 
Inclusion criteria followed the PICOST (Participants, Interven- 
ions, Comparators, Outcomes, Study design, Time periods) frame- 
ork, 1) Participants: Children diagnosed as AICH and infected 
ith one or two or more of hepatitis A, B, C, D and E viruses.
ge was younger than or equal to 14 years old, but no restric- 
ions on gender or race. 2) Interventions: This could be CGI, or 
GI combined with the comparator. 3) Comparators: These could 
e either conventional western medicine (CWM), placebo or no 
reatment. 4) Outcomes: Primary outcomes were indexes related to 
iver function, including total bilirubin (TBiL), alanine aminotrans- 
erase (ALT) and aspartate transaminase (AST). 15 , 16 Secondary out- 
omes included global improvement of symptoms, the disappear- 
nce rate and duration of icterus, adverse events. For the global 
mprovement of symptoms, these were classified into two levels: 
ffective and ineffective. If the clinical symptoms (vomiting, fever, 
ausea, etc) did not improve or even deteriorated compared with 
efore treatment, this was recorded as ineffective. Otherwise they 
ould be called effective. The effective rate = (number of effec- 
ive participants / total number of participants) × 100%. 5) Study 
esign: Only RCT(s) were included. 6) Time periods: All lengths of 
reatment time and duration of follow-up were eligible. For out- 
omes reported at multiple time points, we used the longest re- 
orted follow-up time point. 
.1.2. Exclusion criteria 
1) The full text of articles could not be obtained; 2) any dupli- 
ated articles; 3) Clinical trial protocols. 
.2. Retrieval platforms and search strategies 
PubMed, Web of Science, SinoMed, China National Knowledge 
nfrastructure (CNKI), Wanfang Database, the China Science Tech- 2 ology Journal Database (VIP) were searched from their inception 
o August 15, 2020. The search terms include Fu Fang Gan Cao Suan 
an, Fu Fang Gan Cao Tian Su, Mei Neng, Pai Gan Neng, Gan Yan, 
uang Dan, Compound Glycyrrhizin, Hepatitis, Icteric and Icterus. 
earch strategies for all the electronic databases can be found in 
upplement-Appendix 1. 
We updated the search and selected the latest published trials 
hat met the inclusion criteria, as to May 15, 2021. 
.3. Trial selection and data extraction 
Trials were selected according to the inclusion/exclusion criteria 
y reading the titles, abstracts and (or) full texts of the published 
rticles. 
Two authors extracted the data independently from the in- 
luded trials using a pre-designed data extraction sheet, evaluated 
nd cross-checked. The entries of extraction include article titles, 
uthors’ information, characteristics of participants (sample size, 
ge and disease severity, etc), details of interventions and com- 
arators, outcomes, information relevant to trial design, etc. Any 
isagreements were resolved by discussions with a third author 
JPL). 
.4. Risk of bias 
The risk of bias of each included trial was evaluated using the 
ochrane risk of bias tool 2.0 17 by two authors independently. The 
nconsistencies were discussed with the third author (JPL). The tool 
onsists of the following five domains: randomization process, de- 
iations from the intended interventions, missing outcome data, 
easurement of the outcome and selection of the reported result. 
ach domain was judged as low risk of bias, high risk of bias, or 
ome concerns. 
.5. Data synthesis 
The data were synthesized descriptively, including summary 
tatistics and detailed tables of trial characteristics. 
With regard to the outcomes of CGI for AIHC, the data was 
ooled by conducting meta-analysis, if data allowed, by using Re- 
iew Manager 5.4 (Revman 5.4, Copenhagen: The Nordic Cochrane 
entre, The Cochrane Collaboration) software. We presented binary 
ata as a risk ratio (RR) with its 95% confidence interval (CI), and 
ontinuous data as a mean difference (MD) with its 95% CI. The 
andom-effects model was used for meta-analysis considering po- 
ential sources of clinical heterogeneity. If P < 0.10, this indicated 
hat there was heterogeneity among the included trials. Mean- 
hile, we also referred to the value of I 2 . The smaller the value
f I 2 , the smaller the statistical heterogeneity. 18 When P < 0.10 
nd I 2 ˃ 50%, the accuracy of the data was checked first. If the 
ata was accurate, subgroup analysis based on children’ baseline, 
nterventions and comparators and/or sensitivity analysis based on 
ethodological quality would be conducted, if appropriate, to ex- 
lore the source of heterogeneity. Otherwise, we would interpret 
he result carefully. 
The following subgroup analyses would be conducted, accord- 
ng to the protocol, if appropriate: 1) Subgroup analysis based on 
he severity of AIHC, to detect whether the seriousness of AIHC 
as an impact on the effects; 2) Subgroup analysis based on the 
ifferent courses of treatment, to see whether children can ben- 
fit more from long-term treatment; 3) Subgroup analysis based 
n medication dosage of CGI, to explore whether children can get 
ore benefit from a high dosage. 
Although planned, we did not construct funnel plots to evalu- 
te publication bias as these are inaccurate when fewer than 10 
rials are included in the analysis. 19 In addition, the certainty of 
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he evidence for each outcome was assessed using GRADE (Grad- 
ng of Recommendations Assessment, Development and Evaluation 
riteria) approach 20 to conduct management recommendations by 
he GRADEpro Guideline Development Tool (GDT) online ( https: 
/gradepro.org/ ). 
. Results 
.1. Literature search and selection 
A total of 3371 records were identified by searching electronic 
atabases. We excluded 1840 duplicate records, and 1489 records 
ere excluded by screening the titles and abstracts. The remain- 
ng 42 records were selected by screening full-texts, and 36 were 
emoved for various reasons (see Fig. 1 ). No new randomized con- 
rolled trial was included after an updated retrieval and selection, 
p to May 15, 2021. 
Finally, six articles (representing six individual trials 21–26 ) were 
ncluded in this review. Fig. 1 provides the flow diagram on the 
earch and screening of trials. 
.2. Characteristics of included trials 
Six two-armed RCTs 21–26 involving 608 participants were in- 
luded in this review, all were published in Chinese. The age range 
f participants was 2-12 years old according to four trials 21 , 24–26 , 
nd the ratio of boys to girls was 1.2: 1. Four trials 21–23 , 26 reported 
he types of hepatitis of the participants and the number of par- 
icipants corresponding to each type of hepatitis. Participants in 
ach of these four trials 21–23 , 26 involved viral hepatitis type A, vi- 
al hepatitis type B and mixed hepatitis. Only one trial 26 reported 
he severity of icterus, including 66 mild, 25 moderate and 3 se- 
ious cases. In all trials, the intervention was CGI plus comparator 3 nd the administration of CGI was an intravenous drip. The chil- 
ren in the comparator group were treated with CWM (potassium 
agnesium aspartate, creatinine, vitamin C and/or an energy mix- 
ure, etc). The treatment course of included trials was either 14 or 
5 days duration. 
The characteristics of all the included trials are summarized in 
able 1 . 
.3. Assessment of risk of bias 
The risk of bias summary and graph of included trials is given 
n Fig. 2 . 
a) Domain 1: Risk of bias arising from the randomization process 
For random sequence generation, one trial 25 used the method 
f random number tables, one trials 24 used lot-drawing, and the 
ther four trials 21–23 , 26 only mentioned “random” or “randomiza- 
ion” without describing their methods in detail. For allocation 
oncealment, no trial reported relevant information. If allocation 
oncealment was not implemented, there is reason to suspect that 
he enrolling investigator or the participant had knowledge of the 
orthcoming allocation. Therefore, this domain for all the 21–26 in- 
luded trials was judged as “some concerns” due to insufficient in- 
ormation. 
a) Domain 2: Risk of bias due to deviations from the intended inter- 
ventions 
Although one 25 trial reported using a double-blind design and 
he other five trials 21–24 , 26 did not report blinding information, 
udged in the light of the interventions and comparators, it was 
mpossible to blind the clinicians implementing treatments. Taking 
he above into consideration, deviations from the intended inter- 

















































Characteristics of the included studies. 
ID Sample size (M/F) Age (years) Type of hepatitis (No. of 
participants for each type) 




T C T C T C T C T C 
Huang 
LL2016[21] 










Not reported 60-80ml Compound 
glycyrrhizin injection 
dissolving in 250ml 5% 
glucose solution, ivgtt 
qd ( + Comparator) 
Conventional western 
medicine (30ml PMA 
dissolving in 250ml 5% 
glucose solution, ivgtt 
qd; 0.2g creatinine, 20g 
vitC, 150ml energy 
mixture qd) 
15 1 © 2 © 4 ©
Wang 
WF2015[22] 






Not reported 10-60ml Compound 
glycyrrhizin injection, 
ivgtt qd ( + Comparator) 
Conventional western 
medicine (5-20ml PMA, 
ivgtt; creatinine, vitC, 
energy mixture, etc) 
14 1 © 2 © 3 © 4 ©
Liu 
JL2015[23] 






Not reported 50ml Compound 
glycyrrhizin injection 
ivgtt qd ( + comparator) 
Conventional western 
medicine (25ml PMA, 
ivgtt qd; creatinine, 
vitC, energy mixture, 
etc) 
14 1 © 2 © 3 © 4 ©
Yang 
M2020[25] 




Not reported Not reported 60ml Compound 
glycyrrhizin injection 
dissolving in 250ml 5% 
glucose solution, ivgtt 




14 1 © 2 © 3 © 4 ©
Chen 
QJ2016[26] 
42/39 41/40 2-7 3-7 Not reported Not reported 20ml Compound 
glycyrrhizin injection, 
ivgtt qd ( + comparator) 
Conventional western 
medicine (1g PMA, 
ivgtt qd; 0.2g creatinine 
and 2g vitC dissolving 
in 5% glucose solution, 
ivgtt qd) 
14 4 © 5 ©
Liu 
M2012[27] 
53/41 6.8 ±1.4 
(3-11) 





dissolving in 250ml 5% 
glucose solution, ivgtt 
qd ( + Comparator) 
Conventional western 
medicine (30ml PMA 
dissolving in 250ml 5% 
glucose solution, ivgtt 
qd; creatinine, vitC, 
energy mixture) 
14 4 © 5 ©
A, Viral hepatitis type A; B, Viral hepatitis type B; C, Comparator group; ivgtt, intravenous drip; M, male; Mixed, mixed hepatitis; PMA, Potassium magnesium aspartate; qd, Once a day; T, Treatment 
(intervention) group. 
Outcomes: 
1 © ALT, Alanine aminotransferase 
2 © AST, Aspartate aminotransferase 
3 © TBiL, Total bilirubin 
4 © Global improvement of symptoms 
5 © Duration of icterus. 
4
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nformation about deviations. Therefore, all trials 21–26 were judged 
s “some concerns” in this domain. 
a) Domain 3: Risk of bias due to missing outcome data 
All trials 21–26 were judged as “low risk of bias” in missing out- 
ome data domain as the probably complete, or nearly complete 
utcome data available. 
a) Domain 4: Risk of bias in measurement of the outcome 
According to the interventions and comparators the included 
rials 21–26 reported, all trials 21–26 were impossible to blind the clin- 
cians implementing treatments. What’s more, all trials 21–26 did 
ot report whether they blinded the outcome assessors, as well as 
hey did not report the information of potential conflict of interest. 
aking the above into consideration, all trials 21–26 were judged to 
e of “some concerns” in measurement of the outcome. 
a) Domain 5: Risk of bias in selection of the reported result 
No trial reported information on their trial protocol and regis- 
ration. We could not judge whether these trials 21–26 have selec- 
ively reported outcomes. Therefore, all trials 21–26 were judged as 
some concerns” in this domain. 5 According to the evaluation results of each domain, the overall 
ias was assessed as “high risk of bias” in all the included trials. 
.4. Outcomes 
.4.1. Primary outcomes (indexes related to liver function) 
.4.1.1. Total bilirubin (TBiL). A total of three trials 22–24 reported 
his outcome and reported the change in TBiL levels before and 
fter treatment. A pooled result ( Fig. 3 -A) showed that there was a 
tatistical difference between the intervention and the comparator 
roups (MD = -8.19 mmol/L, 95% CI -9.86 to -7.53, P < 0.0 0 0 01),
hat is, CGI plus CWM was superior to CWM alone for AIHC in re- 
ucing the levels of TBiL. 
.4.1.2. Alanine aminotransferase (ALT). Four trials 21–24 reported the 
hange of ALT levels. Meta-analysis ( Fig. 3 -B) showed that CGI plus 
WM might be better than CWM alone in reducing the levels of 
LT and there were statistical differences (MD = -24.09 U/L, 95% 
I -30.83 to -17.34, P < 0.0 0 0 01). Because of the large heterogene-
ty ( I 2 = 92%) between the four trials, we planned to explore the 
ource of heterogeneity through subgroup analysis or sensitivity 
nalysis. However, we failed to carry out relevant analyses owing 
S.-B. Liang, W.-B. Hou, R.-X. Zheng et al. Integrative Medicine Research 11 (2022) 100772 










































o insufficient information provided by the included trials. Nev- 
rtheless, we considered that the large heterogeneity of statistics 
ay be related to clinical heterogeneity (e.g., disease severity, dif- 
erent treatment courses, different drug doses, or some other clin- 
cal practice factors). 
.4.1.3. Aspartate transaminase (AST). Four trials 21–24 reported AST 
nd all focused on the change in ALT levels before and after treat- 
ent. A result ( Fig. 3 -C) from the four trials showed that there was
 statistical difference (MD = -18.67 U/L, 95% CI -21.88 to -15.45, 
 < 0.0 0 0 01; large statistical heterogeneity, I 2 = 66%) between in-
ervention and comparator group, that is, CGI plus CWM may be 
etter than CWM alone in reducing AST levels. An attempt to ex- 
lore the source of large statistical heterogeneity subgroup analysis 
r sensitivity analysis was not possible due to the insufficient in- 
ormation being provided by the included trials. 
.4.2. Secondary outcomes 
.4.2.1. Global improvement of symptoms. All the included tri- 
ls 21–26 reported this outcome. A pooled result ( Fig. 3 -D) showed 
hat there was a statistical difference between the intervention and 
omparator groups in improving effective rate (RR = 1.20, 95% CI 
.13 to 1.29, P < 0.0 0 0 01), that is, CGI plus CWM had better effects
han CWM alone for AIHC on the global improvement of symp- 
oms. 
.4.2.2. The disappearance rate or duration of icterus. 
Disappearance rate of icterus 6 No trial reported on the outcome of icterus disappearance rate. 
Duration of icterus 
Two trials 25 , 26 reported the duration of icterus. Of these, one 
rial 25 showed that there was a statistical difference between in- 
ervention and comparator groups (MD -6.10 days, 95% CI -6.92 to 
5.28, P < 0.0 0 0 01), that is, CGI plus CWM was better than CWM
lone in shortening the duration of icterus. The second trial 26 re- 
orted that “the duration of icterus in the intervention group was 
.5 ± 2.1days, which was significantly shorter than that in the 
omparator group”. 
.4.2.3. Adverse events. None of the included trials reported this 
utcome. 
.5. Subgroup analysis 
Due to the low number of publications and the lack of infor- 
ation reported in the publications, our review was unable to 
onduct subgroup analyses according to the preset conditions: the 
everity of AIHC, the different duration of treatment and the med- 
cation dosage of CGI. 
.6. Certainty of evidence (GRADE) 
Using the GRADE system recommendation approach, the cer- 
ainty of the evidence for outcomes were all evaluated as low or 
ery low. The certainty of the evidence was downgraded mainly 
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Table 2 
GRADE evaluation form of evidence certainty. 
Patient or population: Acute Icteric Hepatitis in Children 
Setting: Hospital 
Intervention: Compound glycyrrhizin injection plus conventional western medicine 
Comparator: Conventional western medicine 
Outcomes Anticipated absolute effects ∗ (95% CI) Relative effect (95% CI) № of participants 
(studies) 
The certainty of the 
evidence (GRADE) 
Risk with comparator Risk with intervention 
TBiL MD 8.19 lower (9.86 lower 
to 6.53 lower) 
- 232 (3 RCTs) 22-24  
LOW a , b 
ALT MD 24.09 lower (30.83 
lower to 17.34 lower) 
- 352 (4 RCTs) 21-24  
VERY LOW a , b 
AST MD 18.67 lower (21.88 
lower to 15.45 lower) 
- 352 (4 RCTs) 21-24  
VERY LOW a , b 
global improvement of 
symptoms 
766 per 1,000 920 per 1,000 (866 to 989) RR 1.20 (1.13 to 1.29) 608 (6 RCTs) 21-26  
LOW a , b 
The duration of icterus MD 6.1 lower (6.92 lower 
to 5.28 lower) 
- 162 (1 RCT) 25  
LOW a , b 
∗ The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparator group and the relative effect of the intervention 
(and its 95% CI). CI: Confidence interval; MD: Mean difference; RR: Risk ratio; Factors of downgrade: 
a Risk of bias (high risk of detection bias and/or reporting bias) 
b Inconsistency (significant statistical heterogeneity and/or small overlap of 95% CI of different trial results) GRADE Working Group grades of evidence: High certainty: 
We are very confident that the true effect lies close to that of the estimate of the effect. Moderate certainty: We are moderately confident in the effect estimate: The true 
effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. Low certainty: Our confidence in the effect estimate is 
limited: The true effect may be substantially different from the estimate of the effect. Very low certainty: We have very little confidence in the effect estimate: The true 




























































ue to risk of bias (high risk of detection bias or reporting bias), 
nconsistency (significant statistical heterogeneity, or small overlap 
f 95% CI of different trial results). Table 2 provides a summary of 
he certainty of available evidence. 
. Discussion 
.1. Summary of the main findings 
As mentioned earlier, one of the factors leading to AIHC is chil- 
ren’s imperfect organ development and low immune system func- 
ion. Moreover, AIHC can also lead to further impairment of liver 
unction in children. The results of liver function examination for 
hildren with AIHC showed that the levels of children’s total biliru- 
in (TBiL), alanine aminotransferase (ALT) and aspartate transami- 
ase (AST) were significantly increased. Therefore, it is essential to 
mprove the liver function of children with AIHC. In clinical prac- 
ice, one of the important indexes for judging the improvement of 
iver function is whether the levels of TBiL, AST and TBIL decrease 
o a normal level. The results of our review demonstrated that CGI 
lus CWM was better than CWM alone in reducing the levels of 
BiL, ALT and AST. That is, CGI may have adjuvant therapeutic ef- 
ects on improving the liver function of children with AIHC. 
In addition, the other treatment goals for children with AIHC 
re to eliminate the symptom of icterus and other symptoms (e.g., 
omiting, fever, nausea). The results from one trial suggested that 
ombining CGI with CWM was about six days shorter than for 
WM alone for eliminating icterus. In terms of the global improve- 
ent of symptoms, CGI combined with CWM to treat AIHC is su- 
erior to that of CWM alone. A pooled result showed that the ef- 
ective rate of global improvement of symptoms in the CGI group 
as 94.08% (286/304), which was approximately 17% higher than 
hat of the control group (76.64%, 233/304), and was similar to the 
ffective rate of all trials reporting this outcome (92.31% to 95.74%). 
In conclusion, the use of CGI plus CWM in the treatment of 
IHC may be an effective choice. 
.2. Implications for the clinical practice 
All the interventions in the included trials compared CGI with 
GI plus CWM. There were no trials included that examined the 7 se of CGI alone to treat AIHC. The evidence in this review indi- 
ated that CGI may have adjuvant therapeutic effects on the treat- 
ent of children with AIHC. Therefore, we suggest that CGI, com- 
ined with CWM, could be useful in the treatment of AIHC. The 
WM includes potassium magnesium aspartate, creatinine, vitamin 
 and/or energy mixtures, etc. However, whether CGI alone can be 
sed to treat AIHC needs further study in the future. 
The course of treatment for all the included studies was either 
4 or 15 days duration. Therefore, we suggest that CGI could be 
sed for at least 14 days in clinical practice. It is unclear whether 
 more prolonged the use of CGI will provide greater benefit to 
hildren. Safety of long term use also requires investigation. The 
ose of CGI ranged from 10 to 80 ml in light of the characteristics 
f the included trials. However, we failed to perform a subgroup 
nalysis for different doses as planned, so the optimum number of 
oses to provide most benefit still needs clarification and is worthy 
f further exploration. 
.3. Strengths and limitations 
This is the first systematic review, as far as we know, related to 
CTs on the therapeutic effects and safety of CGI for AIHC. This re- 
iew provides better evidence for clinical practice to further evalu- 
te and verify the therapeutic effects of CGI for children with AIHC 
n improving their liver function. There are also limitations. No trial 
ith low risk of bias was included and the sample sizes were small 
n the included trials and safety data was lacking. 
.4. Suggestions and implications for future research 
According to the problems identified in the included RCTs, the 
ollowing suggestions are proposed for future relevant RCTs, 
a) Use of an appropriate random allocation method (e.g., random 
number tables), with detailed reporting. In addition, the ran- 
domization should be properly concealed when participants are 
randomly assigned (e.g., numbered and light-tight sealed en- 
velopes) to ensure the effective implementation of randomiza- 
tion. 
b) Ensure blinding of participants, physicians, outcome assessors 
and data analysts. The aims of blinding are to remove bias (per- 


















































formance bias and detection bias). 27–29 For instance, partici- 
pants and those evaluating the data from the trial do not have 
a preference for one treatment above another. 28 
c) Use of the appropriate method to estimate the sample size of 
participants to ensure the reliability and validity of the study 
results. 30 
d) Development of a detailed study protocol which is registered on 
the relevant website in advance. Related websites include clin- 
icaltrials.gov ( www.clinicaltrials.gov ), Chinese ClinicalTrial Reg- 
istry (ChiCTR, www.chictr.org/cn ), and etc. The study protocol 
can be developed with reference to the SPIRIT 2013 Statement: 
Defining standard protocol items for clinical trials. 31 , 32 Mean- 
while, it is suggested that a standardized report should be for- 
mulated with reference to the Consolidated Standards of Re- 
porting Trials (CONSORT) statement. 33 
e) The last and most important issue is about the safety of med- 
ication for children. As children are a special population, at- 
tention to the safety of children’s medication is critical. How- 
ever, according to the reports of outcomes in the included RCTs, 
the safety of CGI in the treatment of AIHC has not been given 
enough attention. Therefore, it is suggested that the safety of 
CGI used in AIHC should be evaluated and reported in the fu- 
ture. 
.5. Conclusion 
Low or very low certainty evidence demonstrated that CGI has 
pparent adjuvant therapeutic effects on improving the liver func- 
ion of children with AIHC. CGI plus CWM was better than CWM 
lone in reducing the levels of TBiL, ALT and AST, on the global im- 
rovement of symptoms and in shortening the duration of icterus. 
here was no evidence to determine the safety of CGI for AIHC. 
As current evidence is weak, further well-designed RCTs are re- 
uired for verification of the therapeutic effects of CGI. 
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